High CTBP2 expression levels correlate with poor prognosis in prostate cancer patients, while CTBP2 suppresses cancer-inhibiting genes and AR inhibitory factors, such as NCOR and RIP140, by binding to their transcription regulatory regions in prostate cancer cells [28]. Here, NRIP1 is linked to prostate carcinoma.